GLP-1. See this on X. Some exciting new GLP-1 drug randomized trial evidence for *potential* disease-modifying impact on #Parkinsons disease (there are none). No progression of motor disability in the Rx group for 12 months.
Is VKTX really worth 8+ billion and ALT only 600 million?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.